News

Filter News By

Clear Filters

  1. CF Foundation Awards Leading Research Organization Funding to Screen for Potential B. Cepacia Therapy

    January 14, 2020

    The Cystic Fibrosis Foundation awarded nearly $700,000 to Calibr, the drug discovery and development arm of Scripps Research, to screen for a compound that could be used to treat Burkholderia cepacia complex infections.

  2. Circuit Court Rules on ACA in Texas v. United States

    December 19, 2019

    On Dec. 18, the Fifth Circuit Court of the United States issued a decision in Texas v. United States, ruling the individual mandate unconstitutional but sending the case back down to the district court for further review about the fate of the entire Affordable Care Act.

    Topics:

  3. Foundation Announces 2020 Volunteer Leadership Conference Co-Chairs

    December 13, 2019

    Ray Poole and Julie Riedy to lead efforts in Washington, D.C., for volunteer conference, Until CF Stands for Cure Found.

    Topics:

  4. Cystic Fibrosis Foundation Is Exploring New CFTR Modulators

    October 24, 2019

    The Cystic Fibrosis Foundation announced today that it has licensed a compound to the biopharmaceutical company AbbVie to develop into a potential CFTR modulator treatment.

  5. CF Foundation Celebrates FDA Approval of Triple Combination

    October 21, 2019

    The U.S. Food and Drug Administration has approved the use of the triple-combination modulator elexacaftor/tezacaftor/ivacaftor (Trikafta™) for people with cystic fibrosis ages 12 and older who have at least one copy of the F508del mutation.

  6. Enterprise Therapeutics Awarded Up to $7M to Develop Mucus-Clearance Drug for People With CF

    October 15, 2019

    The Cystic Fibrosis Foundation has awarded up to $7 million to Enterprise Therapeutics to develop a compound that targets a non-CFTR chloride channel in lung cells. If successful, the drug could help mucus become more hydrated and easier to clear from the lungs of all people with CF, regardless of their CFTR mutations.

    Topics:

More Posts View All Posts

Related Content

Follow Us On